The US Food and Drug Administration (FDA) has issued emergency use authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg, the investigational neutralizing antibody of Eli Lilly and Company (Lilly) for the treatment of mild to moderate Covid-19. Bamlanivimab has been authorized to be used in adults and pediatric patients, aged 12 years and older with a […]
Eli Lilly and Company has entered into a global antibody manufacturing collaboration with Amgen to considerably boost the supply capacity for its potential COVID-19 therapies. Currently, Lilly is studying various potential neutralizing antibodies for the prevention and/or treatment of the novel coronavirus as monotherapy or in combination. Through the collaboration, the two US pharma companies […]
Continue reading …Coronavirus antibody trial : US pharma giant Eli Lilly and Company (Lilly) said that patients have been dosed in a phase 1 clinical trial with the investigational antibody LY-CoV555 for the treatment of COVID-19. LY-CoV555 is the first antibody candidate to emerge from Lilly’s collaboration with AbCellera Biologics, which was announced in March 2020, with […]
Continue reading …Lilly acquisition of Loxo Oncology : US pharma giant Eli Lilly and Company (Lilly) has signed an all-cash deal worth $8 billion to acquire Loxo Oncology, a Connecticut-based biopharma company, as per the latest pharma acquisition news. Lilly acquisition of Loxo Oncology The acquisition of Loxo Oncology is expected to expand the scope of Lilly’s […]
Continue reading …